CompletedNCT05318924
Effects of Ghrelin Administration on Dopamine and Effort
A short description of this study’s research objective has not yet been verified.
Medication studyAges 20–50GermanyDepression
Understand this study
Who was this study for?
Listed age limits: 20 years to 50 years.
- Listed locations
- Tübingen, GermanySee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Registry last updated: · Record retrieved: . These dates do not confirm site availability.
Study information
Study start dateStarted: February 21, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 26
- Sponsor
- University Hospital Tuebingen
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Germany
- Age range
- From 20 Years to 50 Years
- Official registry ID
- NCT05318924
- Official title
- Will Work for Reward: Effects of Ghrelin Administration on Dopamine and Effort
Recruitment & locations
CompletedTübingen
Questions about this study
Who is behind this study?
The study sponsor is University Hospital Tuebingen, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Ghrelin.
Who was this study for?
Listed age limits: 20 years to 50 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT03039192
Intranasal Esketamine for depression
This study is completed in the United States, in Bulgaria, in Estonia, .... It is testing intranasal Esketamine for depression.
CompletedEUCTR 2008-007483-42
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedEUCTR 2011-005992-17
A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects with Treatment-Resistant Depression
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.